
Adalimumab therapy, regardless of clinical response, improves common hematologic abnormalities such as anemia, thrombocytosis, and leukocytosis in patients with hidradenitis suppurativa.


coremsg

Treatment with adalimumab was associated with improvements in common hematologic abnormalities in patients with hidradenitis suppurativa, particularly in responders.

Adalimumab Improves Blood Parameters in Patients With HS

adalimumab-therapy-improves-hematologic-abnormalities-in-patients-with-hidradenitis-suppurativa


Adalimumab Therapy Improves Hematologic Abnormalities in Patients with Hidradenitis Suppurativa
